OncXerna Therapeutics Reports P-II Trial Results of Bavituximab + Pembrolizumab and New Xerna TME Panel Biomarker Data for Advanced Hepatocellular Carcinoma
- The P-II trial evaluating bavituximab + pembrolizumab in 28 patients at the University of Texas Southwestern Harold C. SCCC
- The results showed that patients treated with bavituximab + pembrolizumab achieved a 62.5% response rate in biomarker positive subgroup & the combination therapy was well tolerated with no new safety signals. The results were presented at ASCO GI 2023
- The results reinforce the potential of the Xerna TME panel to identify patients who are more likely to benefit from targeted & immune therapies across multiple malignancies. The tumor biopsy analysis revealed that the response rate was increased in Xerna TME biomarker-positive patients while biomarker-negative patients experienced higher rates of progressive disease
Ref: OncXerna | Image: OncXerna
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.